CS
ASBPW

Clear Street’s Aspire Biopharma Warrant ASBPW Stock Holding History

Clear Street’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.49K Sell
330,664
-100
-0% -$2 ﹤0.01% 996
2025
Q4 		$5.46K Sell
330,764
-106,500
-24% -$3.28K ﹤0.01% 823
2025
Q3 		$13.1K Buy
437,264
+106,200
+32% +$5.37K ﹤0.01% 668
2025
Q2 		$14.8K Hold
331,064
– – ﹤0.01% 481
2025
Q1 		$22.4K Buy
331,064
+192,598
+139% +$11.6K ﹤0.01% 288
2024
Q4 		$6.58K Sell
138,466
-100
-0.1% -$3 ﹤0.01% 386
2024
Q3 		$5.86K Buy
138,566
+85,567
+161% +$4.07K ﹤0.01% 446
2024
Q2 		$2.38K Sell
52,999
-100
-0.2% -$4 ﹤0.01% 580
2024
Q1 		$1.6K Hold
53,099
– – ﹤0.01% 603
2023
Q4 		$3.19K Sell
53,099
-1,400
-3% -$58 ﹤0.01% 501
2023
Q3 		$2.76K Sell
54,499
-2
-0% – ﹤0.01% 756
2023
Q2 		$2.73K Sell
54,501
-1,583
-3% -$58 ﹤0.01% 913
2023
Q1 		$2.34K Sell
56,084
-97,194
-63% -$6.42K ﹤0.01% 831
2022
Q4 		$12K Buy
153,278
+6,227
+4% +$418 ﹤0.01% 478
2022
Q3 		$16K Buy
147,051
+133,230
+964% +$19.4K ﹤0.01% 514
2022
Q2 		$2K Buy
+13,821
New +$3.01K ﹤0.01% 859

Other funds holding ASBPW

MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Clear Street's ASBPW Position: Q1 2026 in Review

Clear Street reduced its Aspire Biopharma Warrant (ASBPW) stake by 0.03% in Q1 2026, selling an estimated $2 and leaving 330,664 shares worth $5.49K. The position accounts for ﹤0.01% of the portfolio, ranked #996.

Clear Street first reported a position in ASBPW in Q2 2022 and has held it in 16 quarters since. The position peaked at $22.4K in Q1 2025. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

  • Clear Street held 330,664 shares of Aspire Biopharma Warrant worth $5.49K as of Q1 2026.
  • Clear Street sold 100 Aspire Biopharma Warrant shares in Q1 2026, an estimated $2.
  • Aspire Biopharma Warrant made up ﹤0.01% of Clear Street's portfolio in Q1 2026, its #996 holding.
  • Clear Street first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 16 quarters since.
  • Clear Street's Aspire Biopharma Warrant position peaked at $22.4K in Q1 2025.
  • 29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on Clear Street's 13F filing for Q1 2026, filed 15 May 2026.